Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 2/3 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NETWORK 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 119Paclitaxel 104Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 73Dexamethasone 60Cyclophosphamide 60Pemetrexed 57durvalumab 55Bevacizumab 55Capecitabine 54Radiotherapy 51Doxorubicin 51Oxaliplatin 50Fluorouracil 48Radiation 47Rituximab 43Leucovorin 43Vincristine 41Lenalidomide 40Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 32Bortezomib 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × luprolide acetate gel depot × 90 days × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡